Johnson & Johnson (NYSE:JNJ) Shares Sold by CapWealth Advisors LLC

CapWealth Advisors LLC lessened its stake in Johnson & Johnson (NYSE:JNJ) by 0.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 139,567 shares of the company’s stock after selling 429 shares during the period. Johnson & Johnson makes up about 2.7% of CapWealth Advisors LLC’s investment portfolio, making the stock its 14th biggest position. CapWealth Advisors LLC’s holdings in Johnson & Johnson were worth $21,876,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in JNJ. Bond & Devick Financial Network Inc. increased its holdings in shares of Johnson & Johnson by 6.4% in the third quarter. Bond & Devick Financial Network Inc. now owns 6,531 shares of the company’s stock valued at $1,017,000 after purchasing an additional 393 shares during the last quarter. Worth Financial Advisory Group LLC increased its stake in Johnson & Johnson by 4.9% during the third quarter. Worth Financial Advisory Group LLC now owns 11,537 shares of the company’s stock worth $1,797,000 after acquiring an additional 542 shares during the last quarter. Ritholtz Wealth Management increased its stake in Johnson & Johnson by 90.9% during the third quarter. Ritholtz Wealth Management now owns 41,394 shares of the company’s stock worth $6,447,000 after acquiring an additional 19,714 shares during the last quarter. Arkadios Wealth Advisors increased its stake in Johnson & Johnson by 54.3% during the third quarter. Arkadios Wealth Advisors now owns 71,925 shares of the company’s stock worth $11,202,000 after acquiring an additional 25,298 shares during the last quarter. Finally, Venture Visionary Partners LLC increased its stake in Johnson & Johnson by 0.4% during the third quarter. Venture Visionary Partners LLC now owns 99,877 shares of the company’s stock worth $15,558,000 after acquiring an additional 373 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Morgan Stanley cut their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Bank of America dropped their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, April 15th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.86.

Johnson & Johnson Trading Up 0.3 %

NYSE:JNJ opened at $149.56 on Wednesday. The firm has a market cap of $360.41 billion, a PE ratio of 9.32, a price-to-earnings-growth ratio of 2.44 and a beta of 0.53. The stock has a fifty day moving average price of $155.83 and a 200 day moving average price of $155.51. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. Johnson & Johnson’s revenue was up 2.3% compared to the same quarter last year. During the same period last year, the business posted $2.68 earnings per share. Sell-side analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.32%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s payout ratio is 30.92%.

Insiders Place Their Bets

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.